Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Other Accumulated Expenses: 2020-2024

Historic Other Accumulated Expenses for Tango Therapeutics (TNGX) over the last 5 years, with Dec 2024 value amounting to $1.7 million.

  • Tango Therapeutics' Other Accumulated Expenses fell 37.04% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 37.04%. This contributed to the annual value of $1.7 million for FY2024, which is 34.81% up from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Other Accumulated Expenses is $1.7 million, which was up 34.81% from $1.3 million recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Other Accumulated Expenses registered a high of $1.7 million during FY2024, and its lowest value of $666,000 during FY2021.
  • For the 3-year period, Tango Therapeutics' Other Accumulated Expenses averaged around $1.4 million, with its median value being $1.3 million (2023).
  • In the last 5 years, Tango Therapeutics' Other Accumulated Expenses decreased by 16.02% in 2021 and then surged by 90.24% in 2022.
  • Tango Therapeutics' Other Accumulated Expenses (Yearly) stood at $793,000 in 2020, then decreased by 16.02% to $666,000 in 2021, then soared by 90.24% to $1.3 million in 2022, then grew by 1.58% to $1.3 million in 2023, then spiked by 34.81% to $1.7 million in 2024.